Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.1636
-0.0230 (-12.33%)
At close: Nov 20, 2026, 4:00 PM EST
0.1666
+0.0030 (1.83%)
After-hours: Nov 20, 2026, 7:46 PM EST
Vistagen Therapeutics Employees
Vistagen Therapeutics had 41 employees as of June 30, 2026. The number of employees decreased by 16 or 28.07% compared to the same quarter last year. That makes Vistagen Therapeutics the 35,888th largest employer in the world and 4,861st in the United States.
Employees
41
Change (1Y)
-16
Growth (1Y)
-28.07%
Revenue / Employee
$58,073
Profits / Employee
-$1,437,634
Market Cap
7.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 41 | -16 | -28.07% | 41 | 0 |
| Mar 31, 2026 | 41 | -16 | -28.07% | 41 | 0 |
| Dec 31, 2025 | 59 | 11 | 22.92% | 59 | 0 |
| Sep 30, 2025 | 59 | 14 | 31.11% | 59 | 0 |
| Jun 30, 2025 | 57 | 16 | 39.02% | 57 | 0 |
| Mar 31, 2025 | 57 | 17 | 42.50% | 56 | 1 |
| Dec 31, 2024 | 48 | 11 | 29.73% | 48 | 0 |
| Sep 30, 2024 | 45 | 12 | 36.36% | 45 | 0 |
| Jun 30, 2024 | 41 | 9 | 28.13% | 41 | 0 |
| Mar 31, 2024 | 40 | 6 | 17.65% | 39 | 1 |
| Dec 31, 2023 | 37 | 5 | 15.63% | 37 | 0 |
| Sep 30, 2023 | 33 | -1 | -2.94% | 33 | 0 |
| Jun 30, 2023 | 32 | -6 | -15.79% | 32 | 0 |
| Mar 31, 2023 | 34 | -2 | -5.56% | 33 | 1 |
| Dec 31, 2022 | 32 | 1 | 3.23% | 32 | 0 |
| Sep 30, 2022 | 34 | 8 | 30.77% | 34 | 0 |
| Jun 30, 2022 | 38 | 14 | 58.33% | 38 | 0 |
| Mar 31, 2022 | 36 | 15 | 71.43% | 36 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| BioLineRx | 24 |
| Lisata Therapeutics | 21 |
| IN8bio | 20 |
| Radiopharm Theranostics | 14 |
| CalciMedica | 12 |
| Cellectar Biosciences | 11 |
| Immuron | 8 |
VTGN News
- 8 days ago - Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Vistagen Therapeutics Quarterly report: Q2 2027 - Filings
- 8 days ago - Vistagen Therapeutics Earnings release: Q2 2027 - Filings
- 12 days ago - Vistagen provides regulatory update following Type C meeting with the FDA - TheFly
- 12 days ago - Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder - GlobeNewsWire
- 4 weeks ago - Vistagen selects GATC Health to apply predictive AI to drug development - TheFly
- 4 weeks ago - Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs - GlobeNewsWire
- 1 month ago - SRX Global says adds investment in Onconetix - TheFly